Serotonin syndrome in stroke patients.
DOI:
https://doi.org/10.2340/16501977-1924Keywords:
serotonin syndrome, stroke, dopaminergic agent.Abstract
OBJECTIVE: Serotonin syndrome is a potentially life-threatening condition that can be caused by administration of agents that increase serotonergic activity in the brain. We report here on 2 stroke patients who presented with serotonin syndrome following administration of dopaminergic agents. CASE REPORT: Two stroke patients were administered ropinirole (patient 1) and carbidopa/levodopa (patient 2) during rehabilitation. Both patients exhibited the clinical features of serotonin syndrome, coinciding with an increase in dosage of each drug. Based on the clinical features included in revised Radomski's criteria, they presented with 3 major symptoms with 3 and 2 minor symptoms, respectively. The drugs that were thought to trigger serotonin syndrome were discontinued and the patients underwent conservative treatment. The patients recovered completely from the symptoms of serotonin syndrome appearing 2 days after administration of the trigger drugs. CONCLUSION: Because a considerable number of stroke patients have some limitation in communication, and serotonin syndrome is a potentially life-threatening condition, clinicians should pay particular attention to the potential for development of serotonin syndrome when prescribing these drugs to stroke patients.Downloads
Downloads
Published
How to Cite
Issue
Section
License
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.